# A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

> **NCT03670888** · PHASE1 · TERMINATED · sponsor: **JHL Biotech, Inc.** · enrollment: 1 (actual)

## Conditions studied

- B Cell Lymphoma

## Interventions

- **BIOLOGICAL:** JHL1101
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT03670888
- **Lead sponsor:** JHL Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-16
- **Primary completion:** 2019-03-19
- **Final completion:** 2019-03-19
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The development was stopped due to company's strategy consideration
- **Last updated:** 2020-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03670888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03670888, "A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT03670888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*